About Lysophosphatidic acid receptor 2
Lysophosphatidic acid receptor 2 (LPAR2) is a protein
from Homo sapiens identified by UniProt accession
Q9HBW0, 348 residues long.
MolForge cross-references it against 0 known binders and
173 disease associations.
Target properties
| Protein name | Lysophosphatidic acid receptor 2 |
|---|
| UniProt accession | Q9HBW0 |
|---|
| Gene | LPAR2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 348 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (173)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.24
- neurodegenerative disease · score 0.23
- multiple sclerosis · score 0.22
- Parkinson disease · score 0.22
- lysosomal storage disease · score 0.22
- Alzheimer disease · score 0.22
- lymphocyte percentage of leukocytes · score 0.20
- neutrophil percentage of leukocytes · score 0.16
- basophil count · score 0.16
- basophil percentage of leukocytes · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9HBW0-F1 | alphafold | PREDICTED | 85.58 | — |
Amino-acid sequence (348 residues)
MGQCYYNETI GFFYNNSGKE LSSHWRPKDV VVVALGLTVS VLVLLTNLLV IAAIASNRRF HQPIYYLLGN LAAADLFAGV AYLFLMFHTG PRTARLSLEG WFLRQGLLDT SLTASVATLL AIAVERHRSV MAVQLHSRLP RGRVVMLIVG VWVAALGLGL LPAHSWHCLC ALDRCSRMAP LLSRSYLAVW ALSSLLVFLL MVAVYTRIFF YVRRRVQRMA EHVSCHPRYR ETTLSLVKTV VIILGAFVVC WTPGQVVLLL DGLGCESCNV LAVEKYFLLL AEANSLVNAA VYSCRDAEMR RTFRRLLCCA CLRQSTRESV HYTSSAQGGA STRIMLPENG HPLMDSTL
Explore Lysophosphatidic acid receptor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets